Optimal management of patients with the antiphospholipid syndrome (APS) remains a problem. There is now good evidence that those with thrombosis will be subject to recurrences and require long-term, possibly lifelong, oral anticoagulation. Steroids and immunosuppressive drugs aiming at a reduction of the antibody levels have not provided long-term benefit. Only prospective and controlled clinical trials can give a definitive answer to the optimal thrombotic prophylaxis in patients with the APS.
KhamashtaMAAshersonRA. Hughes Syndrome. Antiphospholipid Antibodies move closer to thrombosis in 1994. Br J Rheumatol1995; 34: 493–494
2.
HuntBJKhamashtaMA. Management of the Hughes Syndrome. Clin Exp Rheumatol1996; 14: 115–117
3.
LockshinMD. Answers to the antiphospholipid antibody syndrome?N Engl J Med1995; 332: 1025–1027
4.
KhamashtaMAHughesGRV. Antiphospholipid Syndrome. A common cause of thrombosis. Br Med J1993; 307: 883–884
5.
RivierGHerranzMTKhamashtaMAHughesGRV. Thrombosis and Antiphospholipid Syndrome: a preliminary assessment of three antithrombotic treatments. Lupus1994; 3: 85–90
6.
ViannaJLComparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med1994; 36: 3–9
WallaceDJ. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus. Arthritis Rheum1987, 30: 1435–1436
9.
WallaceDJLinker-IsraeliMMetzgerAStecherVJ. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus1993; 2 (Suppl 1): S13–15
10.
PetriMIncidence of and predictors of thrombotic events in SLE: protective role of hydroxychloroquine. Arthritis Rheum1992; 35 (Suppl): S54
11.
McCraeKR. Antiphospholipid antibody-associated thrombosis: a consensus for treatment?Lupus1996; (in press)
12.
ToubiEKhamashtaMAPanarraAHughesGRV. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med1995; 99: 397–401
13.
BreyRL. Stroke prevention in patients with antiphospholipid antibodies. Lupus1994; 3: 299–302
14.
KhamashtaMAAssociation of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet1990; 335: 1541–1544
15.
CerveraR.et al. High prevalence of significant heart valve lesions in patients with the primary antiphospholipid syndrome. Lupus1991; 1: 43–47
16.
AshersonRALubbeWF. Cerebral and valve lesions in systemic lupus erythematosus: association with antiphospholipid antibodies?J Rheumatol1988; 15: 539–543
17.
Antiphospholipid Antibodies in Stroke Study Group. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. Stroke1990; 21: 1268–1273
18.
KhamashtaMAWallingtonT.Management of the antiphospholipid syndrome. Ann Rheum Dis1991; 50: 959–962
19.
AshersonRAAnticardiolipin antibody, recurrent thrombosis and warfarin withdrawal. Ann Rheum Dis1985; 44: 823–825
20.
KhamashtaMAThe management of thrombosis in the antiphospholipid antibody synrome. N Engl J Med1995; 332: 993–997
21.
RosoveMHBrewerPMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med1992; 117: 303–308
22.
DerksenRHWMDe GrootPHGKaterLNieuwenhuisHK. Patients with antiphospholipid antibodies and venous thrombosis should receive long-term anticoagulant treatment. Ann Rheum Dis1993; 52: 689–692
23.
HirshJHoakJ. Management of deep vein thrombosis and pulmonary embolism. Circulation1996; 93: 2212–2245
24.
De StefanoVFinazziGMannueciM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood1996; 87: 3531–3544
25.
KhamashtaMATaubNAHuntBJ. Thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med1995; 333: 665–667
26.
GinsbergJSAntiphospholipid antibodies and venous thromboembolism. Blood1995, 86: 3685–3691
27.
LimaFA study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol1996; 14: 131–136
28.
KhamashtaMAHughesGRV. Pregnancy in systemic lupus erythematosus. Curr Opin Rheumatol1996; (in press)
29.
Italian Registry of Antiphospholipid Antibodies: Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italian registry. Haematologica1993; 78: 313–318
30.
Alarcon-SegoviaDSanchez-GuerreroJ. Correction of thrombocytopenia with small dose aspirin in the primary antiphospholipid syndrome. J Rheumatol1989; 16: 482–488
31.
DurandJMCorrection of thrombocytopenia with dapsone in the primary antiphospholipid syndrome. J Rheumatol1993; 20: 1777–1778
32.
KavanaughHA. Danazol therapy in thrombocytopenia associated with the antiphospholipid antibody syndrome. Ann Intern Med1994; 121: 767–768
33.
Martin-SuarezICorrection of severe thrombocytopenia with chloroquine in the primary antiphospholipid syndrome. Lupus1996; 5: 81–33
34.
YamazakiMAsakuraHMatsudaT. Resolution of thrombocytopenia in a patient with lupus anticoagulant who received warfarin therapy. Acta Haematol1994; 92: 52–53
35.
PallaresJACabaF. Implicaciones anestesicas en el sindrome an tifosfolipido. Dos Casos Clinicos. Res Esp Anestesiol Reanim1995; 42: 182–185
36.
SingletonJDConyersL. Warfarin and azathioprine: an important drug interaction. Am J Med1992; 92: 217
37.
RivierGKhamashtaMAHughesGRV. Warfarin and azathoprine: a drug interaction does exist. Am J Med1993; 95: 342
38.
AshersonRABaguleyEPalCHughesGRV. Antiphospholipid syndrome: five year follow-up. Ann Rheum Dis1991; 50: 805–810
39.
AshersonRA. The catastrophic antiphospholipid syndrome. J Rheumatol1992; 19: 508–512
40.
GertnerELieJT. Systemic therapy with fibrinolytic agents and heparin for recalcitrant non-healing cutaneous ulcer in the antiphospholipid syndrome. J Rheumatol1994; 21: 2159–2161
41.
CampsMTFibrinolytic treatment in primary antiphospholipid syndrome. Lupus1996; (in press)
42.
ZahaviJIschaemic necrotic toes associated with antiphospholipid syndrome and treated with iloprost. Lancet1993; 342–862
43.
SandovalJPrimary Antiphospholipid Syndrome presenting as chronic thromboembolic pulmonary hypertension. Treatment with thromboendarterectomy. J Rheumatol1996; 23: 772–775
